Daniel Brims
Stock Analyst at Lake Street
(0.04)
# 4,412
Out of 4,429 analysts
22
Total ratings
17%
Success rate
-36.2%
Average return
Main Sectors:
Stocks Rated by Daniel Brims
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KURA Kura Oncology | Initiated Coverage: Buy | $23 | $9.93 | +131.62% | 3 | Jun 4, 2026 | |
| ALGS Aligos Therapeutics | Maintained: Buy | $45 | $5.28 | +752.27% | 2 | Jun 1, 2026 | |
| VKTX Viking Therapeutics | Initiated Coverage: Buy | $89 | $30.38 | +192.96% | 1 | May 28, 2026 | |
| RANI Rani Therapeutics Holdings | Reiterated: Buy | $9 | $0.7824 | +1,050.31% | 1 | May 18, 2026 | |
| PIII P3 Health Partners | Rated: Buy | $962 | $10.75 | +8,848.84% | 1 | May 15, 2026 | |
| LITS Lite Strategy | Reiterated: Buy | $7 | $0.8278 | n/a | 7 | Sep 2, 2015 | |
| IMNN Imunon | Maintained: Buy | $7 | $1.82 | n/a | 6 | Aug 10, 2015 | |
| TSX: BHC Bausch Health Companies Inc. | Maintained: Buy | n/a | $6.57 | n/a | 1 | Dec 30, 2014 |
Kura Oncology
Jun 4, 2026
Initiated Coverage: Buy
Price Target: $23
Current: $9.93
Upside: +131.62%
Aligos Therapeutics
Jun 1, 2026
Maintained: Buy
Price Target: $45
Current: $5.28
Upside: +752.27%
Viking Therapeutics
May 28, 2026
Initiated Coverage: Buy
Price Target: $89
Current: $30.38
Upside: +192.96%
Rani Therapeutics Holdings
May 18, 2026
Reiterated: Buy
Price Target: $9
Current: $0.7824
Upside: +1,050.31%
P3 Health Partners
May 15, 2026
Rated: Buy
Price Target: $962
Current: $10.75
Upside: +8,848.84%
Lite Strategy
Sep 2, 2015
Reiterated: Buy
Price Target: $7
Current: $0.8278
Upside: n/a
Imunon
Aug 10, 2015
Maintained: Buy
Price Target: $7
Current: $1.82
Upside: n/a
Bausch Health Companies Inc.
Dec 30, 2014
Maintained: Buy
Price Target: n/a
Current: $6.57
Upside: n/a